Synairgen plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNG.L research report →
Companywww.synairgen.com
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd.
- CEO
- Richard Marsden
- IPO
- 2004
- Employees
- 36
- HQ
- Southampton, GB
Price Chart
Valuation
- Market Cap
- $11.58M
- P/E
- -0.23
- P/S
- 0.00
- P/B
- 0.15
- EV/EBITDA
- -0.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -51.06%
- ROIC
- -70.80%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-8,408,000 · 52.35%
- EPS
- $-0.04 · 52.28%
- Op Income
- $-10,292,000
- FCF YoY
- 41.34%
Performance & Tape
- 52W High
- $10.00
- 52W Low
- $0.60
- 50D MA
- $1.67
- 200D MA
- $3.35
- Beta
- -2.12
- Avg Volume
- 1.64M
Get TickerSpark's AI analysis on SNG.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SNG.L Coverage
We haven't published any research on SNG.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SNG.L Report →